Bought PKTX .48 x .51...news
p>
VANCOUVER, British Columbia, Canada, Feb. 2, 2004 (PRIMEZONE) -- ProtoKinetix
Inc. (OTCBB:PKTX) is excited to announce that it has entered into an exclusive
agreement with the University of Michigan under which the Company has an
exclusive option to license and develop certain fields of therapeutic products
against breast cancer based upon the Mammastatin molecule, discovered by the
University of Michigan. Dr. John Todd, president of ProtoKinetix, conducted
compassionate clinical trials using Mammastatin that, in several cases, resulted
in the reduction of breast cancer tumor mass.
The Company intends to replicate the binding site of the Mammastatin molecule,
which we believe will mimic the mechanism of action of the Mammastatin protein.
More detailed information on this research will be announced shortly.
About ProtoKinetix:
ProtoKinetix Inc. is a therapeutic development company whose mission is to
develop effective biological therapeutics for the treatment of malignancies.
The company is focused on a new generation of monoclonal antibodies termed
"Super-antibodies." These antibodies are engineered to provide higher
potency and resiliency resulting in vastly enhanced therapeutic impact.
ProtoKinetix will use this technology to create therapeutic antibodies to help
in the treatment of cancer.
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements. Some information included in this
press release contains statements that are forward-looking. Such
forward-looking information involves significant risks and uncertainties that
could affect anticipated results in the future and, accordingly, these results
may differ materially from those expressed in any forward-looking statements
made by or on behalf of the Company. For a description of additional risks and
uncertainties, please refer to the Company's filings with the Securities and
Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President
CONTACT: ProtoKinetix Inc.
Investor Contact:
BCGU, Business Consulting Group Unlimited
In the U.S. (888) 772-1288
Outside the U.S.: +011 (858) 523-0122
www.bcgu.com
To succeed in life. Share your wealth. Help others. God Bless.
EZtradin
